logo
logo
Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

NYSE•DNA
CEO: Dr. Jason Kelly Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-04-19
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
連絡先情報
27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States
877-422-5362
www.ginkgobioworks.com
時価総額
$511.54M
PER (TTM)
-1.5
5.2
配当利回り
--
52週高値
$17.58
52週安値
$5.00
52週レンジ
32%
順位66Top 96.8%
1.5
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 1.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$38.84M-56.38%
直近4四半期の推移

EPS

-$1.45+34.26%
直近4四半期の推移

フリーCF

-$31.61M-73.35%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Loss Narrows Nine months net loss narrowed significantly to $(232.0M) USD; operational loss improved by $211.6M compared to prior year.
Strong Cash Position Maintained Cash and marketable securities total $461.9M USD as of September 30, 2025; sufficient liquidity projected for next twelve months.
Operating Loss Significantly Reduced Operating loss reduced substantially to $(244.5M) USD year-to-date, reflecting successful cost control measures across segments.
Restructuring Charges Decreasing Quarterly restructuring charges decreased to $1.7M USD, showing progress in completing the major workforce reduction plan.

リスク要因

Total Revenue Declines Total revenue declined $46.4M USD year-to-date; Cell Engineering revenue dropped $32.4M USD compared to prior year period.
Non-Cash Revenue Recognition Drop Non-cash revenue recognized fell $50.2M USD for the quarter due to the release of deferred revenue from terminated contracts.
Technology Obsolescence Risk Rapidly changing technology and extensive competition in synthetic biology could make current products obsolete or non-competitive.
Contingent Consideration Liability Contingent consideration liability stands at $5.7M USD; future cash settlements or stock issuances remain a potential obligation.

見通し

Restructuring Completion Expected Workforce reductions from the 2024 restructuring plan are expected to be substantially complete during the remainder of 2025.
Strategic Platform Investment Anticipate continued investment in R&D, Foundry, Codebase, and expansion of new tool offerings like Datapoints and RAC systems.
ATM Proceeds for Operations Intend to use net ATM proceeds, totaling $9.4M USD since inception, for financing operations and technology development.
Facility Consolidation Timeline Facility consolidation efforts continue; timing for subleasing unused space is extended and may not occur prior to 2026.

同業比較

売上高 (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Iovance Biotherapeutics, Inc.IOVA
$250.43M
+175.6%
Valneva SEVALN
$198.55M
+13.5%

粗利益率 (最新四半期)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Astria Therapeutics, Inc.ATXS
100.0%
+0.0pp
Iovance Biotherapeutics, Inc.IOVA
97.9%
+65.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NRIX$1.36B-5.6-57.5%8.1%
GERN$1.15B-15.0-30.3%21.5%
VIR$1.04B-2.1-50.8%9.8%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-4.0%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月24日
|
EPS:-$1.80
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $38.84M-56.4%
    |
    EPS: $-1.45+34.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $49.60M-11.7%
    |
    EPS: $-1.10-74.0%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $48.32M+27.3%
    |
    EPS: $-1.68-49.4%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $227.04M-9.7%
    |
    EPS: $-10.54+42.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $89.05M+60.6%
    |
    EPS: $-1.08-82.6%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $56.21M-30.2%
    |
    EPS: $-4.23+17.8%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $37.94M-53.0%
    |
    EPS: $-3.32-22.4%
    予想通り

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $251.46M-47.4%
    |
    EPS: $-18.37+63.4%
    予想を下回る